Target Audience

This program is designed for comprehensive ophthalmologists.

Learning Objectives: General Sessions

Upon completion of this activity, attendees should be better able to:

  • Compare the efficacy of conventional and new diagnostic modalities, as well as delivery systems, being used in the clinical and surgical ophthalmology practice.
  • Examine complex cataract IOL and refractive cases via video presentations and how comprehensive ophthalmologists can effectively manage these patients.
  • Evaluate new surgical techniques in various ophthalmic subspecialties and conditions.
  • Examine the latest technological advances in cataract surgery, lens and patient selection, as well as preoperative strategies.
  • Describe the latest medical, laser, and surgical advances in glaucoma treatment and management.
  • Evaluate various corneal conditions and diseases, as well as medical and surgical procedures that have been shown to effectively treat these disorders.
  • Evaluate retinal disease, medical and surgical advances, and pertinent clinical trial data to better understand what is essential for a comprehensive ophthalmologist to know to improve patient outcomes.
  • Summarize new information pertaining to the use of oculoplastics in the comprehensive ophthalmology practice.

Learning Objectives: Thursday CME Seminar

Upon successful completion of the activities, participants should be better able to:

  • Summarize newer anti-VEGF injection protocols that may improve the long-term management of diabetic retinopathy and age-related macular degeneration.
  • Examine real-world clinical data that report on patient-related and anatomical factors that influence outcomes in patients being treated for neovascular age-related macular degeneration or diabetic retinopathy.

Learning Objectives: Friday CME Seminar

Upon successful completion of the activities, participants should be better able to:

  • Evaluate new evidence on emerging approaches in drug delivery and gene therapy for the treatment of neovascular retinal diseases.
  • Summarize emerging advances that allow for the targeting of treatment in neovascular retinal diseases.
This continuing medical education activity is jointly provided by

Kiawah Eye 2020 is supported by independent medical education grants from Genentech, Inc.; and Regeneron Pharmaceuticals, Inc.

ACCREDITATION: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Vindico Medical Education and MUSC Storm Eye Institute. Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION: Vindico Medical Education designates this live activity for a maximum of 16.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

FACULTY/PLANNER DISCLOSURE POLICY: In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all planners, teachers, and authors involved in the development of CME content are required to mitigate and disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience.

NOTICE: Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program director and the Office of Medical Affairs and Compliance.